法律とは凄いもんだ、其の運用一つで（〓今回の新型コロナは2023年5月8日から感染症法上の、其の法的根拠の括りが2類から5類に下げられた）世の中がころりと変わる、コロナがまたぞろ増えつつ状況は同じ、人々はこの法律下でこの3年間逼塞した世の中で苦しんだ日々が続いた

最近、周りでコロナに罹ったなんて、云う人が多くなっている、熱と咳の症状です、クリニックの薬剤の処方は、解熱剤を出すだけが多いと聴いた、確かコロナ用の薬剤はもう認可されている筈だが？！

またぞろ、中国から団体客を入れることで、新型コロナが増加するかもしれない、だって世界の感染症を観測して、留意情報を出す錦の御旗の国際機関WHOが新たな変異株EG5の多くは中国由来だとレポートしています、しかし日本での感染症法上での法的根拠上は、もうただの風邪と同じだからとしていますね・・

 

 

コロナ感染、再び急拡大も？ WHOが変異株の新系統を「監視下」に

2023.08.08

2023年に入って新たに確認された新型コロナウイルス（SARS-CoV-2）の変異株「EG.5.1」が、北米や英国などで急速に感染者を増やしている。

ウイルスが公衆衛生に与える影響の大きさにより、それらを分類している世界保健機関（WHO）は7月19日、オミクロン株「XBB.1.9.2」系統の子孫株であるEG.5（特にEG.5.1）を「監視中の変異株（VUM）」のリストに追加した。

コロナ感染、再び急拡大も？ WHOが変異株の新系統を「監視下」に | Forbes JAPAN ...
forbesjapan.com
 

上記リンク外れている場合は→ここ

コロナ感染、再び急拡大も？ WHOが変異株の新系統を「監視下」に | Forbes JAPAN ...
forbesjapan.com
 

 

EG.5 Initial Risk Evaluation, 9 August 2023

EG.5 is a descendent lineage of XBB.1.9.2, which has the same spike amino acid profile as XBB.1.5. EG.5 was first reported on 17 February 2023, and designated as a variant under monitoring (VUM) on 19 July 2023. With this risk evaluation, we are designating EG.5 and its sub-lineages as a variant of interest (VOI).
EG.5 carries an additional F456L amino acid mutation in the spike protein compared to the parent XBB.1.9.2 subvariant and XBB.1.5. Within the EG.5 lineage, the subvariant EG.5.1 has an additional spike mutation Q52H and represents 88% of the available sequences for EG.5 and its descendent lineages.
As of 7 August 2023, 7354 sequences of EG.5 have been submitted to GISAID from 51 countries. The largest portion of EG.5 sequences are from China (30.6%, 2247 sequences). The other countries with at least 100 sequences are the United States of America (18.4%, 1356 sequences), the Republic of Korea (14.1%, 1040 sequences), Japan (11.1%, 814 sequences), Canada (5.3%, 392 sequences), Australia (2.1%, 158 sequences), Singapore (2.1%, 154 sequences), the United Kingdom (2.0%, 150 sequences), France (1.6%,119 sequences), Portugal (1.6%, 115 sequences), and Spain (1.5%, 107 sequences).
Globally, there has been a steady increase in the proportion of EG.5 reported. During epidemiological week 29 (17 to 23 July 2023), the global prevalence of EG.5 was 17.4%. This is a notable rise from the data reported four weeks prior (week 25, 19 to 25 June 2023), when the global prevalence of EG.5 was 7.6%.
Based on the available evidence, the public health risk posed by EG.5 is evaluated as low at the global level, aligning with the risk associated with XBB.1.16 and the other currently circulating VOIs (see risk evaluation table below). While EG.5 has shown increased prevalence, growth advantage, and immune escape properties, there have been no reported changes in disease severity to date. While concurrent increases in the proportion of EG.5 and COVID-19 hospitalizations (lower than previous waves) have been observed in countries such as Japan and the Republic of Korea, no associations have been made between these hospitalizations and EG.5. However, due to its growth advantage and immune escape characteristics, EG.5 may cause a rise in case incidence and become dominant in some countries or even globally.
WHO and its Technical Advisory Group on SARS-CoV-2 Evolution (TAG-VE) continue to recommend that Member States prioritize specific actions to better address uncertainties relating to antibody escape and severity of EG.5. The suggested timelines are estimates and will vary from one country to another based on national capacities:
• Share information on the growth advantage of EG.5 in your country and/or provide sequence information (1-4 weeks).
• Conduct neutralization assays using human sera, representative of the affected community(ies), and EG.5 live virus isolates (2-4 weeks, see table below for the results from previously conducted).
• Perform a comparative evaluation to detect changes in rolling or ad hoc indicators of severity (4-12 weeks, see table below for the results from previously conducted studies).
The WHO and its Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continue to regularly assess the impact of variants on the performance of COVID-19 vaccines to inform decisions on updates to vaccine composition.(2)
The risk evaluation below is based on currently available evidence and will be revised regularly as moreevidence and data from additional countries become available.
15

Amongst the VOIs and VUMs featuring the F456L mutation and for the period 19 June to 23 July 2023, EG.5 is most reported at 49.1%, compared to other VOI and VUM including XBB.1.16.6 (4.88%), FL.1.5.1 (4.41%), XBB.1.5.10 (4.06%), XBB.1.5.72 (3.52%), EG.6.1 (3.26%), FD.1.1 (3.07%), EG.5.2 (3.06%), FE.1.1 (2.58%), FL.15 (2.47%), FE.1.2 (2.09%), XBB.1.5.70 (1.91%), GK.1 (1.83%), FE.1.1.1 (1.68%), XBB.1.5.59 (1.31%), XBB.1.5 (1.27%), GN.1 (1.26%), XBB.1.16.9 (1.15%), FL.1.5 (1.08%), and XBB.1.9.1 (1.07%), among others withreported prevalence less than one percent.

 

https://www.who.int/docs/default-source/coronaviruse/09082023eg.5_ire_final.p...
www.who.int
 
The following two tabs change content below.

村松社長

旅行産業界に身を置いてはや45年。シンガポール航空社の日本でのB２Bリーディングカンパニーから京都の制御機器メーカー傘下旅行社を経て起業して以来早くも28年目に入りました。このコロナ禍で本当の旅行情報を発信するために旅行WEBマガジンを令和3年に立ち上げる。専門は海外の出張など。趣味：散歩ついでのお地蔵さん・神社お詣り、銭湯巡り、映画鑑賞。